Desvenlafaxine succinate for the treatment of major depressive disorder

Bibliography

• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8
   PubMed Web of Science ®Google Scholar
• Schweizer E, Weise C, Clary C, et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-6
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-34
   PubMed Web of Science ®Google Scholar
• Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-74
   PubMed Web of Science ®Google Scholar
• Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 2006;26:250-8
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99
   PubMed Web of Science ®Google Scholar
• Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007;68:1663-72
   PubMed Web of Science ®Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47
   PubMed Web of Science ®Google Scholar
• Mason JN, Deecher DC, Richmond RL, et al. Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther 2007;323:720-9
   PubMedGoogle Scholar
• DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
   PubMed Web of Science ®Google Scholar
• Alfinito PD, Huselton C, Chen X, Deecher DC. Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague–Dawley rats. Brain Res 2006;1098:71-8
   PubMed Web of Science ®Google Scholar
• Deecher DC, Alfinito PD, Leventhal L, et al. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 2007;148:1376-83
   PubMed Web of Science ®Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
   PubMed Web of Science ®Google Scholar
• Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7
   PubMed Web of Science ®Google Scholar
• Clement EM, Odontiadis J, Franklin M. Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. J Chromatogr B Biomed Sci Appl 1998;705:303-8
   PubMed Web of Science ®Google Scholar
• Klamerus KJ, Maloney K, Rudolph RL, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:716-24
   PubMed Web of Science ®Google Scholar
• Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996;16:915-23
   PubMed Web of Science ®Google Scholar
• Parks V, Patat A, Behrle J. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single oral doses of sustained-release desvenlafaxine succinate (DVS-SR) in healthy subjects [poster presentation]. Presented at: American Society for Clinical Pharmacology and Therapeutics; 2 – 5 March 2005; Orlando, FL
   Google Scholar
• Shilling A, Young-Sciame R, Leung L. Comparison of inhibitory effects of desvenlafaxine succinate, venlafaxine, S,S duloxetine, paroxetine, sertraline and bupropion on human cytochrome P450 activities [poster presentation]. Presented at: International Society for the Study of Xenobiotics; 25 – 27 October 2005; Maui, HI
   Google Scholar
• Feiger AD, Tourian KA, Rosas GR, et al. A placebo-controlled efficacy and safety study of a flexible dose of desvenlafaxine succinate in outpatients with major depressive disorder [poster presentation]. Presented at the 160th Annual Meeting of the American Psychiatric Association; 19 – 24 May 2007; San Diego, California
   Google Scholar
• Liebowitz M, Montgomery S, Boyer P, et al. Evaluation of the efficacy and safety of fixed doses of desvenlafaxine succinate at 50 mg and 100 mg in outpatients with major depressive disorder in 2 placebo-controlled trials [poster presentation]. Presented at: The American College of Neuropsychopharmacology Annual Meeting; 9 – 13 December 2007; Boca Raton, Florida
   Google Scholar
• Rickels K, Montgomery SA, Tourian KA, et al. A multi-center, randomized, double-blind, placebo-controlled, parallel-group study of desvenlafaxine succinate for prevention of depressive relapse in adult outpatients with major depressive disorder [poster presentation]. Presented at: The 160th Annual Meeting of the American Psychiatric Association; 19 – 24 May 2007; San Diego, California
   Google Scholar
• Ferguson J, Tourian KA, Rosas GR, et al. A 12-month open-label evaluation of long-term safety and efficacy of desvenlafaxine succinate in outpatients with major depressive disorder [poster presentation]. Presented at: The 160th Annual Meeting of the American Psychiatric Association; 19 – 24 May 2007; San Diego, California
   Google Scholar
• Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60
   PubMed Web of Science ®Google Scholar
• Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995;10(Suppl 2):15-20
   PubMedGoogle Scholar
• Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Health Syst Pharm 2005;62:2481-90
   PubMed Web of Science ®Google Scholar
• Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-59S; discussion 59S-61S
   PubMed Web of Science ®Google Scholar
• Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30:437-55
   PubMed Web of Science ®Google Scholar
• Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol 2007;22:129-33
   PubMed Web of Science ®Google Scholar
• Ilett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998;45:459-62
   PubMed Web of Science ®Google Scholar
• Ilett KF, Kristensen JH, Hackett LP, et al. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol 2002;53:17-22
   PubMed Web of Science ®Google Scholar
• Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 2007;27:1-5
   PubMedGoogle Scholar
• Khan A, Khan SR, Shankles EB, Polissar NL. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol 2002;17:281-5
   PubMed Web of Science ®Google Scholar
• Carmody TJ, Rush AJ, Bernstein I, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006;16:601-11
   PubMed Web of Science ®Google Scholar
• Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand 1975;51:161-70
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:55-62
   PubMed Web of Science ®Google Scholar
• Thase ME. Treatment of anxiety disorders with venlafaxine XR. Expert Rev Neurother 2006;6:269-82
   PubMedGoogle Scholar
• Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000;157:968-74
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-51
   PubMed Web of Science ®Google Scholar
• Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 1997;58:393-8
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 2006;5:523-37
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Brown CH, Hur K, et al. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007;164:1044-9
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005;62:165-72
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008;65:94-101
   PubMed Web of Science ®Google Scholar
• Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292:338-43
   PubMed Web of Science ®Google Scholar